Ascentage Pharma posts interim results presentation on 1H 2026 business update
AAPG•Cash runway and pipeline progress
Cash runway projected through 2027, supported by commercial sales from olverembatinib and lisaftoclax.
Pipeline focus centered on nine registrational trials, including four global studies; lisaftoclax and olverembatinib advanced global Phase III programs.
APG-3288 BTK degrader remained in Phase I dose escalation, including U.S. enrollment; APG-115 entered China’s Starlight pediatric oncology program.
Management additions and HKEX short name update
Management added Chief Business Officer Faiçal Miyara, Chief Commercial Officer Jim Ziegler; HKEX stock short name removed the “B” marker.
1H 2026 revenue and product sales increased
Ascentage reported 1H 2026 revenue of USD 44.5 million, up 29% year over year; product sales totaled USD 41.6 million.
